Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus (Q33412360)

26 July 2017

0 references

Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus (English)

1 reference

26 July 2017

1 reference

Boaz Hirshberg

1

1 reference

26 July 2017

Artist Parker

2

1 reference

26 July 2017

Helen Edelberg

3

1 reference

26 July 2017

Mark Donovan

4

1 reference

26 July 2017

Nayyar Iqbal

5

1 reference

26 July 2017

1 October 2014

1 reference

Diabetes - Metabolism: Research and Reviews

26 July 2017

1 reference

26 July 2017

30

1 reference

26 July 2017

7

1 reference

26 July 2017

556-569

1 reference

Standards of medical care in diabetes--2013

26 July 2017

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

21 January 2018

1 reference

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

21 January 2018

1 reference

Antidiabetic therapy effects on bone metabolism and fracture risk

21 January 2018

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

21 January 2018

1 reference

Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme

21 January 2018

1 reference

Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells

21 January 2018

1 reference

Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin

21 January 2018

1 reference

Sitagliptin-associated drug allergy: review of spontaneous adverse event reports

21 January 2018

1 reference

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study

21 January 2018

1 reference

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

21 January 2018

1 reference

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

21 January 2018

1 reference

Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial

21 January 2018

1 reference

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.

21 January 2018

1 reference

Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.

21 January 2018

1 reference

Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.

21 January 2018

1 reference

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

Saxagliptin overview: special focus on safety and adverse effects

21 January 2018

1 reference

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

21 January 2018

1 reference

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study

21 January 2018

1 reference

Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial

21 January 2018

1 reference

Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies

21 January 2018

1 reference

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures

21 January 2018

1 reference

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

21 January 2018

1 reference

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.

21 January 2018

1 reference

Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial

21 January 2018

1 reference

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin

21 January 2018

1 reference

Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26)

21 January 2018

1 reference

7 January 2021

Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks

1 reference

7 January 2021

Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus

1 reference

7 January 2021

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.2502

1 reference

26 July 2017

1 reference